Market closed
BioMarin/$BMRN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioMarin
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Ticker
$BMRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
3,401
Website
BioMarin Metrics
BasicAdvanced
$13B
30.88
$2.21
0.28
-
Price and volume
Market cap
$13B
Beta
0.28
52-week high
$94.85
52-week low
$60.63
Average daily volume
1.7M
Financial strength
Current ratio
5.325
Quick ratio
2.963
Long term debt to equity
10.519
Total debt to equity
10.519
Interest coverage (TTM)
45.02%
Management effectiveness
Return on assets (TTM)
5.15%
Return on equity (TTM)
8.05%
Valuation
Price to earnings (TTM)
30.882
Price to revenue (TTM)
4.544
Price to book
2.3
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
26.718
Growth
Revenue change (TTM)
17.97%
Earnings per share change (TTM)
154.02%
3-year revenue growth (CAGR)
15.62%
3-year earnings per share growth (CAGR)
84.75%
What the Analysts think about BioMarin
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
BioMarin Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioMarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioMarin News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $13B as of February 23, 2025.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 30.88 as of February 23, 2025.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.